GLP 1 Agonists News and Research

Latest GLP 1 Agonists News and Research

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

Inhibitex, Inc. today reported positive top-line safety and antiviral data from its multiple ascending dose Phase 1b clinical trial of INX-189, an oral nucleotide polymerase inhibitor being developed to treat chronic infections caused by hepatitis C virus.

31 Mar 2011

FDA grants orphan drug status to America Stem Cell's ASC-101

America Stem Cell, Inc. announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to ASC-101 to improve homing to bone marrow in patients receiving hematopoietic stem cell transplantation.

30 Mar 2011

GI Dynamics announces positive results from EndoBarrier studies against type 2 diabetes

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, announced today new results from three studies that demonstrate the positive effects of the EndoBarrier Gastrointestinal Liner on type 2 diabetes, weight loss and other metabolic factors.

30 Mar 2011

Almac inaugurates new CLIA registered laboratory

Almac's Diagnostics business unit today announced the opening of its CLIA registered laboratory.

30 Mar 2011

Nycomed submits teduglutide MAA to EMA for SBS treatment

NPS Pharmaceuticals, Inc. a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported that Nycomed, a global pharmaceutical company, headquartered in Switzerland, has submitted a Marketing Authorization Application to the European Medicines Agency for clearance to market teduglutide as a once-daily subcutaneous treatment for short bowel syndrome.

29 Mar 2011

Sitagliptin drug can slow onset of diabetes

Diabetes type 2 is caused by insufficient levels of insulin to keep blood glucose under control. Excessive levels of another hormone, glucagon, can also contribute to diabetes type 2 by causing the liver to flood the body with stored glucose.

25 Mar 2011

Type 2 diabetes drug less likely to cause weight gain, raise cholesterol levels

An inexpensive type 2 diabetes drug that has been around for more than 15 years works just as well and has fewer side effects than a half-dozen other, mostly newer and more expensive classes of medication used to control the chronic disease, new Johns Hopkins research suggests.

15 Mar 2011

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.

10 Mar 2011

Redpoint Bio fourth quarter revenues are $0.7 million for 2010

Redpoint Bio Corporation, a company focused on the development of healthier foods and beverages and new approaches to the treatment of diabetes and obesity, today announced financial and operational results for the quarter and year ended December 31, 2010.

5 Mar 2011

Researchers demonstrate potential neurochemical mechanism of weight loss

An interdisciplinary group of researchers at the University of Pennsylvania has, for the first time, identified the neurological and cellular signaling mechanisms that contribute to satiety - the sensation of feeling full - and the subsequent body-weight loss produced by drugs used to treat type 2 diabetes. More comprehensive knowledge of these mechanisms could form the basis for anti-obesity medications.

4 Mar 2011

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company utilizing its proprietary BHT-DNA™ platform to develop novel and targeted autoimmune and immune-mediated disease treatments, today announced the successful clearance of an IND with the US FDA for BHT-3034, a disease-modifying DNA plasmid vaccine immunotherapy for patients with the autoimmune neuromuscular junction disease myasthenia gravis.

1 Mar 2011

EPA approves BioNeutral's Ygiene 206 antimicrobial disinfectant

BioNeutral Group, Inc., a specialty life science technology-based company, today announced that it has received approval and registration from the Environmental Protection Agency (EPA) in response to the Company's regulatory application for its Ygiene™ 206.

28 Feb 2011

TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1b trial of ViaDor-GLP1 agonist, which is being developed for the treatment of diabetes mellitus type II.

22 Feb 2011

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).

18 Feb 2011

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2010.

17 Feb 2011

Numira acquires Ricerca' Efficacy Pharmacology operating unit

Numira Biosciences, a specialty contract research organization and leader in high resolution, 3D imaging services and visualization software for the life science market, announced today that it has acquired the Efficacy Pharmacology operating unit of Ricerca Biosciences, LLC., located in Bothell, WA.

14 Feb 2011

Repligen third quarter total revenue increases 26% to $7,068,000

Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.

9 Feb 2011

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended December 31, 2010.

8 Feb 2011

Particle Sciences announces strategic alliance with HORIBA Instruments

Particle Sciences, Inc., a leading pharmaceutical CRO, is pleased to announce the establishment of a strategic alliance with HORIBA Instruments of Irvine, CA, which is the U.S. sales and marketing division of HORIBA Limited of Kyoto, Japan.

8 Feb 2011

Researchers to develop new diagnostics platform for early detection of lung cancer

The earlier cancers can be detected, the better the chances of a cure. Researchers are now working to develop a new diagnostics platform with which the illness can be diagnosed in its early stages, even during a visit to the general practitioner: protein biomarkers in exhaled air divulge the presence of pathological cells in the lung.

3 Feb 2011

GLP 1 Agonists News and Research

Latest GLP 1 Agonists News and Research

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

FDA grants orphan drug status to America Stem Cell's ASC-101

GI Dynamics announces positive results from EndoBarrier studies against type 2 diabetes

Almac inaugurates new CLIA registered laboratory

Nycomed submits teduglutide MAA to EMA for SBS treatment

Sitagliptin drug can slow onset of diabetes

Type 2 diabetes drug less likely to cause weight gain, raise cholesterol levels

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Redpoint Bio fourth quarter revenues are $0.7 million for 2010

Researchers demonstrate potential neurochemical mechanism of weight loss

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

EPA approves BioNeutral's Ygiene 206 antimicrobial disinfectant

TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Numira acquires Ricerca' Efficacy Pharmacology operating unit

Repligen third quarter total revenue increases 26% to $7,068,000

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

Particle Sciences announces strategic alliance with HORIBA Instruments

Researchers to develop new diagnostics platform for early detection of lung cancer

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

GLP 1 Agonists News and Research

Latest GLP 1 Agonists News and Research

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in